Gout

Main information

  • Trade name:
  • Gout Fighter Plus
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Gout Fighter Plus
    Australia
  • Language:
  • English

Other information

Status

  • Source:
  • Dept. of Health,Therapeutic Goods Administration - Australia
  • Authorization number:
  • 221694
  • Last update:
  • 08-10-2017

Public Assessment Report

Public Summary

Summary for ARTG Entry:

221694

Gout Fighter Plus

ARTG entry for

Medicine Listed

Sponsor

Nature's Sunshine Products of Australia Pty Ltd

Postal Address

PO Box 6884,BAULKHAM HILLS BUSINESS CENTRE, NSW, 2153

Australia

ARTG Start Date

26/03/2014

Product category

Medicine

Status

Active

Approval area

Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in

the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine,

(b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is

sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be

kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records

to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted

in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office

of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors

of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified

of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine

outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National

Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Gout Fighter Plus

Product Type

Single Medicine Product

Effective date

26/03/2014

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

If fluid retention persists, seek medical advice (or words to that effect).

Standard Indications

May help reduce joint inflammation associated with arthritis.

May help reduce joint swelling associated with arthritis.

May help increase joint mobility associated with gout.

Temporary relief of the pain of arthritis. (or) Temporary relief of arthritic pain. [Warning S required]

May help reduce joint swelling associated with gout.

May help reduce joint inflammation associated with gout.

Temporary relief of pain associated with gout. [Warning S required]

Aids, assists or helps in the maintenance or improvement of general well-being.

Diuretic. Aids or assists in the treatment of fluid retention. [Warning FLRET required]

May assist in the management of rheumatism. [Warning S required]

Symptomatic relief or rheumatism. [Warning S required]

Temporary relief of the pain of rheumatism. [or] Temporary relief of rheumatic pain. [Warning S required]

May help increase joint mobility associated with arthritis.

Specific Indications

Traditionally used in herbal medicine to relieve gout symptoms including joint pain, redness, tenderness, warmth and swelling.

Traditionally used in herbal medicine to manage rheumatic symptoms.

Traditionally used in herbal medicine to relieve arthritis symptoms including joint inflammation, pain, redness, stiffness, swelling, tenderness and warmth.

Traditionally used in herbal medicine as an analgesic.

Traditionally used in herbal medicine as a diuretic to help increase the excretion of metabolic waste products.

Traditionally used in herbal medicine as a diuretic to help increase urinary output.

Helps maintain healthy uric acid levels.

Public Summary

Page 1 of

Produced at 26.11.2017 at 12:49:39 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Active Ingredients

Apium graveolens

300 mg

Equivalent: Apium graveolens (Dry)

Prunus cerasus

200 mg

Equivalent: Prunus cerasus (Fresh)

Salix alba

45 mg

Equivalent: Salix alba (Dry)

4.5 g

© Commonwealth of Australia.This work is copyright.You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior

written approval from the Commonwealth.Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.

Public Summary

Page 2 of

Produced at 26.11.2017 at 12:49:39 AEDT

This is not an ARTG Certificate document.

The onus is on the reader to verify the current accuracy of the information on the document subsequent to the date shown.

Visit www.tga.gov.au for contact information

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

There are no news related to this product.